definiens: means, with respect to any Licensed Pro duct sold by the Prostate Cancer Sublicensee or any of its Affiliates or sublicensees, the gross amounts invoiced on sales of such Licensed Product by the Prostate Cancer Sublicensee or any o f its Affiliates or sublicensees to a Third Party purchaser in an arms - length transaction, less the f ollowing customary deductions, determined in accordance with GAAP and internal policies and actu ally taken, paid, accrued or allocated based on good faith estimates : ( i ) trade, cash and/or quantity discounts, allowances, and credits, exclud ing commissions for commercialization ; ( ii ) excise taxes, use taxes, tariffs, sales taxes and c ustoms duties, and/or other government taxes imposed on the sale of Licensed Pr oduct ( including VAT, but only to the extent that such VAT taxes are not reimb ursable or refundable ), specifically excluding, for clarity, any income tax es assessed against the income arising from such sale ; ( iii ) outbound freight, shipment and insurance costs to t he extent inc luded in the price and separately itemized on the invoice price ; ( iv ) compulsory payments to, cash rebates payable to, or the impact of reimbursement caps established by, a governmental authority ( or a gent thereof ) pursuant to governmental regulations by reason of any national or local health insurance program or similar program, including government le vied fees as a result of healthcare reform policies ; ( v ) retroactive price reductions, credits or allowances actually granted upon rejections or returns of Licensed Product, including for recal ls or damaged goods, or billing errors and reserves for returns ; ( vi ) rebates, chargebacks, administrative fees and discounts ( or equivalent thereof ) payable to managed health care organizations, group purchasing organizations, pharmacy benefit managers ( or equivalent thereof ), specialty pharmacy providers, federal, state / provincial, local or other governmen ts, or thei r agencies or purchasers, reimbursers, or trade customers ; ( vii ) amounts payable to patients through co- pay assistance cards or similar forms of rebate directly related to the prescribing of the L icensed Product ; and 4 [ * * * ] INDICATES MATERIAL THAT WAS OMITTED AND FOR W HICH CONFIDENTIAL TREATMENT WAS REQUESTED . ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMEND ED